Both CAR T cell therapies currently approved for the treatment of multiple myeloma, namely idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), are autologous, second-generation CARs directed against B-cell maturation antigen (BCMA). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.